<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04326192</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00020197</org_study_id>
    <nct_id>NCT04326192</nct_id>
  </id_info>
  <brief_title>Brown Adipose Tissue Activation by Spinal Cord Stimulation</brief_title>
  <official_title>Brown Adipose Tissue Activation by Spinal Cord Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate and utilize spinal cord stimulation (SCS) as an&#xD;
      effective approach to eliciting weight loss and potentially alleviating Type 2 diabetes&#xD;
      mellitus (DM), as evidenced by increasing metabolism of adipose tissue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study aims to investigate possible activation of brown adipose tissue (BAT)&#xD;
      metabolism by upper thoracic spinal cord stimulation (SCS). We believe that our&#xD;
      multidisciplinary research team presents a unique opportunity to test whether SCS can&#xD;
      activate BAT metabolism, as tested during a routine screening procedure for spinal cord&#xD;
      stimulation (SCS) for pain control. Our marker for BAT activation is 18F-fluorodeoxyglucose&#xD;
      (FDG) - positron emission tomography (PET), which has previously been used to gauge&#xD;
      cold-evoked BAT activation, and other studies of BAT in humans. We believe this&#xD;
      proof-of-concept study could pave the way for a new therapeutic modality for the treatment of&#xD;
      morbid obesity, and Type 2 Diabetes Mellitus.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SUVmax</measure>
    <time_frame>1 week</time_frame>
    <description>Maximum standardized uptake value (SUVmax) of bilateral cervical and supraclavicular regions during SCS activation, in comparison to baseline imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ipsi- and contralateral BAT during SCS-activation</measure>
    <time_frame>1 week</time_frame>
    <description>A comparison of ipsi- and contralateral BAT during SCS-activation. PET/CT images will be reconstructed as per standard clinical routine.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pain, Back</condition>
  <condition>Obesity, Morbid</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will have two PET/CT scans on days 3 and 5 after SCS electrode implantation: (1) Baseline and (2) SCS-activated. Other than SCS activation, both studies will be conducted under identical conditions. For the first scan, subjects will be randomly assigned to either a baseline (no SCS during PET/CT) or with SCS during PET/CT prior to the day of their first scan. The second scan will complete the sequence with either a baseline or SCS-activated scan, as randomized.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Research electrode</intervention_name>
    <description>A second electrode will be placed percutaneously by Tuohy needle in the epidural space at the same time as the SCS trial implant; at lateral T1-2 area randomly assigned to the left or right side of the lateral epidural space, at the time of the procedure. Placement of electrodes is not experimental, but the placement of a second electrode is a research-driven procedure.</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 21-70 years&#xD;
&#xD;
          2. Persistent neuropathic leg and back pain&#xD;
&#xD;
          3. Subjects who are already planning to undergo SCS for pain&#xD;
&#xD;
          4. Subjects who have not received a prior SCS trial for pain&#xD;
&#xD;
          5. Subjects with a BMI of 25-45, using formula; weight (lb) / [height (in)]2 x 703&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not considering SCS for pain&#xD;
&#xD;
          2. Forensic patient&#xD;
&#xD;
          3. Taking beta blockers&#xD;
&#xD;
          4. Weight change &gt; 5% within last 3 months&#xD;
&#xD;
          5. Habitual tobacco use&#xD;
&#xD;
          6. Habitual excessive alcohol use&#xD;
&#xD;
          7. Pregnancy&#xD;
&#xD;
          8. Decisionally impaired adults&#xD;
&#xD;
          9. Children&#xD;
&#xD;
         10. Neonates&#xD;
&#xD;
         11. Subjects with a BMI of &lt;25 or &gt;45&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Burchiel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kim Burchiel, MD</last_name>
    <phone>503-494-4314</phone>
    <email>burchiek@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Burchiel, MD</last_name>
      <phone>503-494-4314</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Kim J. Burchiel</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Back Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

